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due to CHF within the year and of these, over 36,930 will be
readmitted within 2 months, (14,284 within 30 days). The
annual hospitalisation rate ranged from 12% (NYHA stage I) to
88% (NYHA stage IV). Excluding surgery, the £536 million
spent on CHF in hospitals is comprised of £171 million in A&E
(including paramedic and ambulance costs), £314 million in
general ward costs and £51 million in specialist ward costs.
CONCLUSIONS: The cost of CHF to the NHS is considerable,
with over 60% falling on hospital budgets and 40% of the total
cost (£355 million) being ward costs.
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OBJECTIVE: To investigate factors inﬂuencing initial pharma-
cotherapy for patients with dyslipidemia in primary care setting.
METHODS: Dyslipidemia patients were identiﬁed from a large
US national database of electronic medical records containing
diagnosis, lab and medication information in primary care
setting from 1997 to 2004. Initial pharmacotherapy was deﬁned
as the 1st-antidyslipidemics prescribed if no antidyslipidemics
were given 12-month prior to the initiation. Logistic regression
models used to examine impact of patient demographics, 
clinical characteristics, and comorbidities on three outcomes:
whether 1) any antidyslipidemics; 2) statin in particular; or 3)
combination therapy was initiated. RESULTS: Total 16,578
patients included in analysis. Male and older patients were more
likely to initiate any antidyslipidemics than females (odds ratio
(OR): 1.14) and younger patients (OR: 3.72 for over 65- vs.
under 40-years). Higher LDL-C and triglyceride (TG), and lower
HDL-C were associated with higher probability of initiating any
antidyslipidemics. Patients with coronary heart disease (CHD)
(OR: 1.60), diabetes (OR: 2.42), hypertension (OR: 1.19), other
atherosclerotic disease (OR: 1.52), and obesity (OR: 1.10) were
more likely to initiate any antidyslipidemics than those didn’t
have those co-morbidities. Among patients who started phar-
macotherapy, those with higher LDL-C or CHD or diabetes were
more likely to be on a statin; however, lower HDL-C and higher
TG were associated with lower likelihood of initiating a statin.
Higher TG level (500+ mg/dL) was the only signiﬁcant predictor
for use of combination therapy among antidyslipidemic users at
diagnosis. CONCLUSIONS: High LDL-C, CHD and diabetes
were strong predictors of initiating any antidyslipidemic agents,
and statins in particular for patients with dyslipidemia. That
patients with abnormal HDL-C or TG were less likely to use
statins might reﬂect perceptions about ineffectiveness of statins
in treating these abnormalities. Further studies are needed to
assess long-term use patterns of antidyslipidemics and associated
outcomes in clinical practice.
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OBJECTIVES: To investigate the clinical efﬁcacy of rosuvastatin
in low-density lipoprotein (LDL) lowering therapy, to investigate
the side effect proﬁle of rosuvastatin as compared to other
statins, and to compare the cost of LDL lowering therapy using
rosuvastatin and other statins. METHODS: This study was a ret-
rospective study in patients who took rosuvastatin in the outpa-
tient clinics of Prince of Wales Hospital during the period of July
1, 2004–June 30, 2005. The prescribing pattern, the utilization
pattern and the side effect proﬁle were recorded. Descriptive sta-
tistics were used and continuous data were reported as mean ±
SD. Lipid proﬁle of each patient was examined according to the
ATPIII guidelines. RESULTS: A total of 261 patients (mean age:
64.8 ± 12 years old; 55.6% male) were recruited in the study.
The baseline mean LDL levels were 3.49 ± 1.30 mmol/L prior to
rosuvastatin and 2.25 ± 1.68 mmol/L after treatment. Rosuvas-
tatin raised the LDL goal attainment rate from 28.0% to 74.3%
and the mean percentage reductions of LDL and triglycerides
(TG) were 35.5% and 10.6% respectively. Approximately 4%
of patient had developed side effects including myalgia, elevated
liver enzyme, and dizziness. Only 17.2% of patients had lipid
assessment within 6 weeks and 47.9% had Liver Function Test
(LFT) within 3 months. Nine percent and 13.8% of patients
respectively had never received these tests. The cost of rosuvas-
tatin was between that of the 2 most commonly prescribed
statins, atorvastatin and simvastatin, in Hong Kong. CONCLU-
SION: Rosuvastatin was effective in LDL goal attainment and
lowering of LDL and TG. Liver enzyme and creatine kinase
should be closely monitored in order to use the drug safely. Local
statin utilization guidelines should be established and reinforced
to promote proper use of lipid lowering agents that may lead to
better clinical and economic outcomes.
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OBJECTIVES: Hospices in the U.S are burdened with increas-
ing pharmaceutical costs and therefore should implement drug
formulary as a cost-containment tool. The study aimed at devel-
oping rational hospice formularies for congestive heart failure
and depression conditions based on Multi-Attribute Utility
Theory (MAUT) methodology. Economic impact of the formu-
laries developed in this study was also investigated. METHOD:
MAUT is a systematic method that assists the P&T committee
in selecting appropriate drugs by assessing four drug attributes:
efﬁcacy, safety, cost, and dosage-form related parameters. For
each therapeutic class, members of the P&T committee ranked
and weighted their preferences for different drug attributes and
factors considered important for the ﬁnal drug selection. The
preference values were combined with literature-based factor
values for each drug obtained through systematic literature
review process to give total utility score values for that drug.
Within each therapeutic class, drugs with highest total utility
scores were selected for the formulary. For economic impact eval-
uation, three categories of drug costs (i.e. total drug costs; spe-
ciﬁc-drug costs; and other drug costs related to the condition)
were computed and compared across pre and post-formulary
groups. RESULT: In each condition, all three types of drug costs
were found to be lower in the post-formulary group as compared
to the pre-formulary groups, however, these were not found to
be statistically signiﬁcant. After adjusting for the price differen-
tials, post hoc analyses for the formulary agents showed that on
a per patient day level, about 8 cents and about 44 cents was
saved as a result of implementing depression and CHF formula-
ries respectively. CONCLUSION: The MAUT method was
found to be a useful decision-making tool that assisted in suc-
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cessfully developing condition-speciﬁc formularies. Annually an
estimated $456.00 and $1813.00 drug cost savings could be
achieved by the hospice as a result of implementing depression
and CHF formularies.
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OBJECTIVES: Growing interest in the use of Drug Eluting Stents
(DES) in coronary angioplasty has prompted the Health Care
Agency of the Emilia Romagna Region to draw up recommen-
dations for their appropriate clinical use. Since the adoption of
any new technology necessitates economic appraisal, we have
analyzed the resource consumption by type of angioplasty pro-
cedure as well as the impact on the budget of a cardiology
department. METHODS: A retrospective economic evaluation
has been carried out on the angioplasty procedures performed in
2004 in the Cardiology Department of Reggio Emilia hospital.
Using the Activity Based Costing method, detailed hospital costs
have been estimated for each procedure and compared with the
pertinent Italian DRG fees. RESULTS: In 2004, the Interven-
tional Cardiology Department of Santa Maria Nuova Hospital
in Reggio Emilia performed 806 angioplasty procedures for a
total expenditure of €5,176,268. These were: 93 Plain Old
Balloon Angioplasties (POBA) (€487,329), 401 procedures using
Bare Metal Stents (BMS) (€2,380,071), 249 procedures using
Drug Eluting Stents (DES) (€1,827,386) and 63 MIXED proce-
dures (€481,480). Reimbursement via DRG funding amounted
for €5,816,748 (11% for POBA, 50% for BMS, 31% for DES
and 8% for MIXED procedures). The overall case-mix of the
performed angioplasty procedures generated a positive margin
of about €680,480 between the costs incurred and the reim-
bursement obtained. CONCLUSIONS: Analysis of the case-mix
of procedures revealed that, although the adoption of innovative
technologies increases costs, an overall positive margin between
costs and DRG reimbursements can be achieved. It therefore
emerges that, adherence in clinical practice to the guidelines
designed by the Health Care Agency of the Emilia Romagna
Region is economically sustainable from the point of view of the
hospital-enterprise.
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OBJECTIVES: To review reported economic evaluations of
myocardial perfusion scintigraphy (MPS) for patients with sus-
pected coronary artery disease (CAD); to synthesise and com-
municate two reviews undertaken to support an appraisal of
MPS in this technology by the UK National Institute for Health
and Clinical Excellence (NICE). METHODS: Conduct a sys-
tematic review to identify published studies reporting economic
evaluations comparing diagnostic strategies with and without
MPS in patients with chest pain and/or abnormal resting ECG.
Studies published between 1984 and 2002 were included,
together with two model-based evaluations submitted to NICE
in 2003. Results were summarised by source of data, strategy
comparison and type of patient. Quality of reported studies and
methodological issues were assessed. RESULTS: Twenty-four
studies were identiﬁed: 12 ‘primary’ studies based on analyses of
prospective or retrospective data and 12 studies based on deci-
sion-analytic modelling. Twenty studies were based in the US and
4 in the UK, one of which used data from a range of European
countries. Many studies reported that MPS was a cost-effective
alternative to Exercise ECG (ExECG) prior to coronary angiog-
raphy (CA) in patients at intermediate/high risk of CAD. Evi-
dence for the cost-effectiveness of adding MPS after ExECG (in
patient’s positive on ExECG) was less conclusive. Compared
with MPS, direct CA was generally not cost-effective in patients
at intermediate risk, but cost-saving for patients at high risk.
Studies were of variable quality; for example primary studies
based on short term outcomes, and failure to present incremen-
tal comparisons. The use of CA as a gold standard for functional
imaging tests which provide additional information to the degree
of vessel stenosis may be problematic. CONCLUSION: There 
is evidence for the cost-effectiveness of MPS in patients at 
intermediate risk of CAD. It would be valuable to conﬁrm this
with longer term prospective studies and improved economic
modelling.
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OBJECTIVES: To estimate the drug acquisition cost savings for
third payer payers (TPPs) with the availability of generic sim-
vastatin in the United States. METHODS: A deterministic study
ascertained the potential cost savings for TPPs in the year fol-
lowing generic simvastatin availability. The study focused on
patients requiring cholesterol reduction (>30% LDL-C reduc-
tion). Annual national statin prescription sales (November
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